摘要
目的分析自体外周血造血干细胞移植（APBSCT）治疗恶性淋巴瘤的临床疗效及安全性。方法自1995年12月至2005年12月，采用APBSCT联合大剂量化疗治疗恶性淋巴瘤31例。平均4周期常规诱导化疗后行APBSC动员及采集。动员方案：非霍奇金淋巴瘤（NHL）病人采用常规剂量CHOP方案，霍奇金淋巴瘤（HL）病人采用高剂量单药CTX4g／m^2。预处理方案：异环磷酰胺（IFO）12g／m^2CTX4g／m^2，阿糖胞苷（Ara—C）4．5g/m^2，足叶乙甙（Vp-16）0．75g／m^2。移植后对原发灶直径大于4cm或有肿瘤残留的病灶给予局部补量放疗。结果31例病人移植后缓解时间为1N108mo，中位缓解期43mo。其中1年无病生存26例（83．9％），2年23例（74．1％），3年21例（67．7％）。全组无移植相关死亡。结论APBSCT联合大剂量化疗治疗恶性淋巴瘤的疗效明显优于常规化疗且安全性高值得推广。
Objective To study the efficacy and safety of autologous peripheral blood stem cell transplantation （APBSCT）. Methods 31 patients with malignant lymphoma were treated by APBSCT combined with high dose chems. APBSCT was aroused and collected after 4 cycle routine induction chems. Routine CHOP regimen was used by non-Hodgkin lymphoma and high dose CTX4g/m^2 was used by Hodgkin lymphoma. Pretreatment regimen was iphosphamide （12g/m^2 ） or CTX （4g/m^2）, arabinosylcytosin （4.5g/m^2） and NSC-141540 （0.75g/m^2）. Primary loci in diameter more than 4 cm or residual loci were reinforced by local radiotherapy after the transplantation. Results Relief time of 31 patients were 1-108 months after the transplantation, medium relief time was 43 months. 26 （83.9%） were one year survival without the disease, 23 （74.1%） were two year survival, and 21（67.7%） were three year survival. The death related to the transplantation was not found. Conclusions The efficacy and safety of autologous peripheral blood stem cell transplantation combined with high dose chems in treatment of malignant lymphoma are better than routine chems and are extended.
出处
《世界肿瘤杂志》
2006年第2期101-103,共3页
Tumour Journal of the World
关键词
自体外周血造血干细胞
大剂量化疗
淋巴瘤
治疗
Autologous peripheral blood stem cell transplantation
high dose chems
malignant lymphoma
treatment
